1. Home
  2. ATGL vs GLSI Comparison

ATGL vs GLSI Comparison

Compare ATGL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Technology Group Limited

ATGL

Alpha Technology Group Limited

N/A

Current Price

$11.00

Market Cap

241.3M

Sector

N/A

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$19.80

Market Cap

277.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATGL
GLSI
Founded
2017
2006
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
241.3M
277.0M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
ATGL
GLSI
Price
$11.00
$19.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
1.3K
135.7K
Earning Date
01-27-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.01
$7.78
52 Week High
$50.00
$34.10

Technical Indicators

Market Signals
Indicator
ATGL
GLSI
Relative Strength Index (RSI) 37.70 41.61
Support Level $10.52 $8.57
Resistance Level $16.08 $29.89
Average True Range (ATR) 0.82 2.20
MACD 0.02 -0.21
Stochastic Oscillator 8.49 40.59

Price Performance

Historical Comparison
ATGL
GLSI

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Share on Social Networks: